



FY12 Results Presentation

Andrew Grech – Managing Director
Wayne Brown – CFO

Not a problem.

**Slater &
Gordon**
Lawyers



Disclaimer

This document has been prepared by Slater & Gordon Limited (**Slater & Gordon**) and comprises written materials/slides for a presentation concerning Slater & Gordon.

This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Slater & Gordon that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Slater & Gordon and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Slater & Gordon disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Slater & Gordon since the date of this presentation.



Key Points

- **\$217.7m group revenue and 26.7% EBITDA* (normalised) for Australian business exceeds guidance after stronger H2**
- **Strong EPS growth (FY12 normalised* EPS up 10% year on year)**
- **Defensive growth characteristics – consistently outperforming ASX Small Ordinaries Index average**
- **Organic growth in core Australian Personal Injuries practice groups exceeded the target range of 5-7%**
- **Strategic diversification provides long term organic growth upside:**
 - UK business off to good start in line with expectations
 - Conveyancing and Family Law practices in Australia primed for double digit revenue growth
- **Cash flow from operations below guidance of 65-70% of NPAT* (normalised) due to billing being weighted to June 2012 more strongly than expected**
- **VIOXX – \$10.5m write-down of WIP and disbursements impacting full year profit (non-cash impact)**

** Normalised for VIOXX impact and acquisition costs in FY12*



FY12 – Business Highlights

- **Consolidated presence in Queensland and NSW post acquisitions of Trilby Misso and Keddies in FY11:**
 - Trilby Misso continuing to grow organically
 - Stronger second half by former Keddies practices – now integrated into Slater & Gordon NSW practice – provides solid platform for future organic growth
- **Expanded service offerings:**
 - Acquisition of Conveyancing Works, the largest specialist conveyancing firm in Australia and roll-out of new conveyancing model nationally on track
 - Family Law fixed fee product launched, nationally now the largest family law practice in Australia
- **Expanded into the UK via acquisition of Russell Jones & Walker:**
 - Delivers geographic expansion and diversification in market 4-5 times that of Australia
 - New platform for long term growth
- **Continued strong results in client and staff satisfaction surveys:**
 - Client satisfaction survey results show continuing improvement with achievement of 91% client satisfaction levels in most recent survey (March 2012)
 - Employee satisfaction survey results show continuing improvement satisfaction levels rising to 86% in most recent survey (April 2012)

FY12 – Financial Results

	FY12 \$M	FY11 \$M	\$M change	% change
Revenue	217.7	182.3	35.4	↑19.4%
Normalised EBITDA ⁽¹⁾	57.6	49.9	7.7	↑ 15.4%
Normalised EBITDA Margin ⁽¹⁾	25.9%	27.7%		
Normalised EBIT ⁽¹⁾	53.9	47.2	6.7	↑14.2%
Normalised EBIT Margin ⁽¹⁾	24.2%	26.2%		
Normalised NPAT ⁽¹⁾	33.4	28.9	4.5	↑15.6%
Vioxx write-off / Acquisition Costs	12.0	1.4		
NPAT (post Vioxx)	25.0	27.9	(2.9)	↓10.5%
	Cents	Cents	Cents change	% change
Basic EPS	16.2	19.1	(2.9)	↓15.2%
Basic EPS (Normalised) ⁽²⁾	21.0	19.1	1.9	↑10.1%
Diluted EPS (Normalised) ⁽²⁾	20.4	18.3	2.1	↑11.5%
Full Year Dividend	6.0	5.5	0.5	↑ 9.1%


1. Normalised for VIOXX impact in FY12 and acquisition costs in FY11 & FY12

2. Normalised for VIOXX impact in FY12 only

Track Record Since Listing

REVENUE


\$m



CAGR Revenue since
listing 29%

EBITDA*

\$m



CAGR EBITDA* (normalised)
since listing 27%

* EBITDA CAGR has been normalised for acquisition costs in each year and Vioxx (FY12)

Cash Flow Conversion

- **Australian Cash Flow from Operations 50% of NPAT – below guidance range of 65%-70% due to increased billing in June**
- **Variance of 2.5% between average monthly seasonality and June 2012 equates to \$6m in cash collections (fees, GST and disbursements) and when collected results in a CFOps of 69%**

	FY11 \$M	FY12 \$M
Normalised NPAT ¹	29.4	32.9
Cash Flow from Operations	20.0	16.6
Recovery of Abnormal June Billings	-	6.0
Adjusted Cash Flow from Operations		22.6
% Recovery	68%	69%

- **Incremental improvement in targeted Cash Flow conversion in FY13:**
 - Changed practice area mix in Australia with lower working capital requirements
 - New geographic area (UK) with beneficial cash flow impact on a full year basis
 - Disbursement funding moved to new external provider, reducing reliance on internally generated cash flow
 - Continued shift of class action funding requirements to third party litigation funders

➤ **Australian Personal Injuries:**

- Deliver steady organic growth notwithstanding competitive and legislative threats
- Exploit scale to build efficiency
- Provide internal funding program for accelerated organic growth in non-PI areas

➤ **Australian non-PI:**

- Continued expansion to meet demands of clients for consumer legal services other than in personal injuries litigation
- Continued emphasis on client and third party funded work to build predictable revenue growth in the non personal injuries litigation practices
- Roll-out successful Conveyancing Works model nationally
- Build profitability of national Family Law practice

➤ **UK:**

- First priority is to settle business into the S&G group and deliver forecast results
- Set stage for long term growth plans

➤ **Revenue:**

- Deliver consistent 5% - 7% organic revenue growth in Australian Personal Injuries practices
- Deliver 8% - 10% organic revenue growth in UK business
- Build sustainable high growth national practices in Conveyancing and Family Law

➤ **Earnings Growth:**

- Exploit scale efficiencies in Personal Injuries practice group to translate revenue growth into incrementally higher earnings growth
- Build Family Law, Conveyancing and Wills to minimum EBITDA margin of 15% within two years

➤ **Cash:**

- Over time cash from operations will improve by a combination of diversifying the business mix, use of external disbursement funding in personal injuries practices and litigation funding in the class action practice

- Australian PI business expected to continue to enjoy 5%+pa organic revenue growth
- UK business on track to achieve acquisition FY13 forecast revenue of \$72m¹
- Combined revenue target of \$290m¹
- EBITDA margin target of 24% - 25%
- Cash from Operations as a % of NPAT target >70%

Why Invest?

- **Strong financial performance since listing – against the general market trend**
- **Australian PI business continues to deliver predictable revenue and earnings growth**
- **UK business provides future growth platform in market 4-5 times that of Australia**
- **Potential to exploit S&G brand in Australian non-PI markets still largely untapped**
- **Financial metrics expected to further improve:**
 - Incremental margin improvement in personal injuries practices through scale of Australian business
 - Less share dilution as M&A activity reduced
 - Cash flow from operations to trend up with changing business mix, new disbursement funding and class action litigation funding
 - Net debt to peak at \$115m (well within banking covenants) and then reduce in FY14



For further information visit
www.slatergordon.com.au

or contact

Andrew Grech

Managing Director

Phone: (03) 9602 6839

Email: agrech@slatergordon.com.au

Not a problem.

**Slater &
Gordon**
Lawyers


Appendix 1: FY12 – Financial Results (Aust vs. UK)

	Aust FY 12 \$M	UK FY 12 \$M	FY 12 \$M	FY 11 \$M	\$M change	% change
Revenue	206.2	11.5	217.7	182.3	35.4	↑ 19.4%
Normalised Revenue*	212.3	11.5	223.8	182.3	41.5	↑ 22.8%
Normalised EBITDA*	56.2	1.4	57.6	49.9	7.7	↑ 15.4%
Normalised EBITDA Margin*	26.7%	12.0%	25.9%	27.7%		
Normalised EBIT*	52.9	1.0	53.9	47.2	6.7	↑14.2%
Normalised EBIT Margin*	25.1%	9.0%	24.2%	26.2%		
Normalised NPAT*	32.9	0.5	33.4	28.9	4.5	↑15.6%
Vioxx write-off / Acquisition Costs	12.0	-	12.0	1.4		
NPAT (post Vioxx)	24.5	0.5	25.0	27.9	(2.9)	↓10.5%

* Normalised for VIOXX impact and
acquisition costs in FY12


Appendix 2: EBIT Bridge

EBIT Contribution
Movement FY11 - FY12



Appendix 3: Cash Flow Conversion - Seasonality

Slater & Gordon Monthly Billing Profile (2nd half of Financial Year)



Variance of 2.5% between average monthly seasonality and June 2012 equates to \$6m (fees, GST and disbursements) and when collected results in a CFOps of 69%

Appendix 4: Benchmarking Slater & Gordon

	FY10	FY11	FY12	3 Year Average	ASX Small Ords Industrials Average FY11
Revenue Growth ¹	21.1%	46.2%	19.4%	28.3%	8.3%
Earnings Growth ^{1,2}	24.2%	50.2%	(5.8%)	20.6%	7.0%
NPAT Growth ¹	16.1%	40.9%	(10.5%)	13.4%	5.3%
Return on Equity ¹	13.5%	14.3%	10.3%	12.7% ³	3.7%
Dividend Growth	17.6%	10.0%	9.1%	12.2%	8.3%
EV / EBIT ⁵	6.7	8.4	7.7	7.6 ³	7.3
EPS Growth	12.6%	6.7%	(6.3%)	5.6%	0.5%
5 Year TSR				48.7% ⁶	(9.3%) ⁴

1. FY12 includes write-down of Vioxx (i.e. not normalised)

2. EBITDA

3. Simple average of 3 years


4. ASX 300 Index used with average dividend yield per annum

5. As at 30 June

6. Based upon SGH share price of \$1.93 on 22 August 2012 and 2012 final dividend of 3.0c

Appendix 5: Australian Personal Injury Practices

**Australian Personal Injuries Practice Groups
Relationship of Enquiries to Revenue**



- Average matter duration for PI matters approximately 2 years
- Strong correlation between enquires and growth in revenue

Appendix 6: Balance Sheet

	FY12	FY11
Debtor Days ¹	108	102
Paid Disbursement Days ¹	49	64
WIP Days (PI) ¹	351	369
WIP Days (Non PI) ¹	13	8
WIP Days (Self Funded Projects) ¹	8	21
Net Debt/Equity	42.8%	22.3%
Interest Cover (times) ^{2,3}	9.2	11.2
Return on Equity ³	13.3%	14.3%

1. Normalised for TML and Keddies transaction in FY11
2. Interest cover based upon interest payments to third parties (i.e. excludes notional interest on deferred consideration)
3. Normalised for Vioxx and acquisition costs

Corporate Snapshot

Slater & Gordon

Slater &
Gordon
Lawyers


ASX Code	SGH
Net Debt (Jun '12)	\$104.2m
Shareholders Equity (Jun '12)	\$243.2m
Employees	1,350
Shares on issue	168.6m
Market Capitalisation	\$325m*

* Based upon share price of \$1.93 as at 22 August 2012

Share Price Performance



Shareholder Profile



Board & Management

John Skippen	Chair
Andrew Grech	Managing Director
Ken Fowle	Executive Director
Ian Court	Non-Executive Director
Erica Lane	Non-Executive Director
Wayne Brown	Chief Financial Officer
Kirsten Morrison	Company Secretary